Drug Profile

Tc 99m nofetumomab merpentan

Alternative Names: F(ab)2 NRLU10 technetium (Tc 99m); OncoTrac; OncoTrac NSCLC; OncoTrac SCLC; Technetium Tc 99m-nofetumomab merpentan; VerLuma

Latest Information Update: 21 Jun 2006

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Poniard Pharmaceuticals
Class Monoclonal antibodies; Monoclonal antibody diagnostics; Organotechnetium compounds; Radiopharmaceuticals; Technetium compounds
Mechanism of Action Single-photon emission-computed tomography enhancers

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

21 Jun 2006 NeoRx Corporation is now called Poniard Pharmaceuticals Inc.
22 May 1997 Launched for Small cell and Non-small cell lung cancer diagnosis in USA (IV)
12 Feb 1997 Registered for Small cell and Non-small cell lung cancer diagnosis in USA (IV)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com